Poulvac IB QX Lyophilisate for Suspension for Spray for Chickens

Țară: Regatul Unit

Limbă: engleză

Sursă: VMD (Veterinary Medicines Directorate)

Ingredient activ:

Infectious bronchitis virus

Disponibil de la:

Zoetis UK Limited

Codul ATC:

QI01AD07

INN (nume internaţional):

Infectious bronchitis virus

Forma farmaceutică:

Lyophilisate for suspension

Tip de prescriptie medicala:

POM-V - Prescription Only Medicine – Veterinarian

Grupul Terapeutică:

Chickens

Zonă Terapeutică:

Live Viral Vaccine

Statutul autorizaţiei:

Authorized

Data de autorizare:

2013-06-27

Caracteristicilor produsului

Revised: November 2021
AN: 00491/2018
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Poulvac IB QX lyophilisate for suspension for spray for chickens
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose contains:
ACTIVE SUBSTANCE:
Live attenuated Avian Infectious Bronchitis Virus, strain L1148
10
3.0
–10
5.0
EID
50
*
.
* EID50 = 50% Embryo Infective Dose.
EXCIPIENT:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate for suspension for spray.
Off-white, beige coloured. Upon reconstitution, transparent to white
opaque
suspension (depending on the volume of diluent used).
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Chickens.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of chickens in order to reduce respiratory
signs of Infectious
Bronchitis caused by QX-like variants of Infectious Bronchitis virus.
Onset of immunity: 3 weeks after vaccination.
Duration of immunity: 63 days after vaccination.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The vaccine virus is capable of spreading to in contact birds for a
minimum of 14
days after vaccination and appropriate care should be taken to
separate vaccinated
from non-vaccinated chickens. Precautionary measures should be taken
to prevent
spreading to wildlife.
Revised: November 2021
AN: 00491/2018
Page 2 of 5
Cleaning and disinfection of the premises after vaccination is
advisable.
This vaccine should only be used after it has been established that
the QX-like IBV
variant strain is epidemiologically relevant.
It is important to avoid introduction of the IB QX vaccine virus into
premises in which
the wild type strain is not present. The IB QX vaccine should only be
applied in
hatcheries if adequate controls are in place to avoid the spread of
the vaccine virus
to birds that will be transported to non-IB QX exposed flocks.
The vaccine has been demonstrated to provide protection against
QX-like variant.
The protection against other circulat